prednisone has been researched along with Fasciitis in 70 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Fasciitis: Inflammation of the fascia. There are three major types: 1, Eosinophilic fasciitis, an inflammatory reaction with eosinophilia, producing hard thickened skin with an orange-peel configuration suggestive of scleroderma and considered by some a variant of scleroderma; 2, Necrotizing fasciitis (FASCIITIS, NECROTIZING), a serious fulminating infection (usually by a beta hemolytic streptococcus) causing extensive necrosis of superficial fascia; 3, Nodular/Pseudosarcomatous /Proliferative fasciitis, characterized by a rapid growth of fibroblasts with mononuclear inflammatory cells and proliferating capillaries in soft tissue, often the forearm; it is not malignant but is sometimes mistaken for fibrosarcoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| " CS plus d-penicillamine (d-Pen) in severe eosinophilic fasciitis." | 9.22 | Severe eosinophilic fasciitis: comparison of treatment with D-penicillamine plus corticosteroids vs. corticosteroids alone. ( Bai, R; Jimenez, SA; Kebede, AG; Mendoza, FA, 2016) |
| "A 23-year-old Australian man developed myalgia and weakness, and later the clinical features of eosinophilic fasciitis, while taking L-tryptophan." | 7.68 | Eosinophilic fasciitis associated with L-tryptophan ingestion. ( de Launey, W; Grigoris, I; Jevtic, AP, 1992) |
| "In a patient with eosinophilic fasciitis, a biopsy specimen obtained within 4 weeks of the onset of symptoms showed infiltration of the subcutis and fascia with mast cells, and there was up to a 19-fold increase in plasma histamine levels." | 7.67 | Increased plasma histamine level in eosinophilic fasciitis. ( Falanga, V; Kerdel, FA; Soter, NA, 1989) |
| "Imatinib mesylate is a multikinase inhibitor of several signaling pathways implicated in skin fibrosis with in vitro antifibrotic activity." | 6.80 | Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. ( Baird, K; Booher, S; Comis, LE; Cowen, EW; Figg, WD; Flanders, KC; Hakim, FT; Joe, GO; Mitchell, SA; Pavletic, SZ; Rose, JJ; Sarantopoulos, S; Steinberg, SM; Takebe, N; Yao, L, 2015) |
| "Eosinophilic fasciitis is a syndrome of imprecise classification which usually responds well to corticosteroids." | 5.27 | [Eosinophilic fasciitis. Response to treatment with cimetidine]. ( Betlloch Mas, I; Castells Rodellas, A; Jiménez Martínez, A; Jorda Cuevas, E; Ramón Quiles, D, 1987) |
| " CS plus d-penicillamine (d-Pen) in severe eosinophilic fasciitis." | 5.22 | Severe eosinophilic fasciitis: comparison of treatment with D-penicillamine plus corticosteroids vs. corticosteroids alone. ( Bai, R; Jimenez, SA; Kebede, AG; Mendoza, FA, 2016) |
| "A 23-year-old Australian man developed myalgia and weakness, and later the clinical features of eosinophilic fasciitis, while taking L-tryptophan." | 3.68 | Eosinophilic fasciitis associated with L-tryptophan ingestion. ( de Launey, W; Grigoris, I; Jevtic, AP, 1992) |
| "A 2-year 10-month old girl developed eosinophilic fasciitis that resolved within one year after the administration of prednisone." | 3.67 | Childhood eosinophilic fasciitis--progression to linear scleroderma. ( Banta, CA; Williams, HJ; Ziter, FA, 1986) |
| "In a patient with eosinophilic fasciitis, a biopsy specimen obtained within 4 weeks of the onset of symptoms showed infiltration of the subcutis and fascia with mast cells, and there was up to a 19-fold increase in plasma histamine levels." | 3.67 | Increased plasma histamine level in eosinophilic fasciitis. ( Falanga, V; Kerdel, FA; Soter, NA, 1989) |
| "Imatinib mesylate is a multikinase inhibitor of several signaling pathways implicated in skin fibrosis with in vitro antifibrotic activity." | 2.80 | Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. ( Baird, K; Booher, S; Comis, LE; Cowen, EW; Figg, WD; Flanders, KC; Hakim, FT; Joe, GO; Mitchell, SA; Pavletic, SZ; Rose, JJ; Sarantopoulos, S; Steinberg, SM; Takebe, N; Yao, L, 2015) |
| "Eosinophilic fasciitis (EF) is an uncommon connective tissue disorder characterized by limb and trunk erythema, with symmetrical thickening of the skin." | 2.72 | Clinical experience with biologic treatment in resistant eosinophilic fasciitis: Case reports and review of the literature. ( Dovrish, Z; Erez, D; Levy, Y; Natour, A; Shoenfeld, Y; Tayer-Shifman, OE, 2021) |
| "Eosinophilic fasciitis (EF) is a rare condition characterized by swelling of the extremities, sclerodermatous evolution and frequent hypereosinophilia." | 2.58 | [Sarcoid-like granulomatosis associated with eosinophilic fasciitis]. ( Bagot, M; Battistella, M; Bouaziz, JD; Guibal, F; Hefez, L; Leonard-Louis, S; Sallé de Chou, C; Vignon-Pennamen, MD; Zuelgaray, E, 2018) |
| "Palmar fasciitis and polyarthritis syndrome (PFPAS) is a rare paraneoplastic syndrome often associated with ovarian and pancreatic cancers, and rarely lung and breast cancers." | 2.47 | Palmar fasciitis with polyarthritis syndrome in a patient with breast cancer. ( Hutchins, LF; Kortebein, PM; Krishna, K; Yacoub, A, 2011) |
| "Eosinophilic fasciitis (EF), described for the first time in 1974 by Shulman, is characterized by induration and inflammation of the fascia of the extremities." | 2.38 | [Eosinophilic fasciitis with aplastic anemia and Hashimoto's thyroiditis. Review of the literature and report of a typical example]. ( Blaser, KU; Speck, B; Steiger, U; Würsch, A, 1989) |
| "A case of diffuse fasciitis with eosinophilia (DFE, or Shulman's disease) is presented." | 2.36 | Diffuse fasciitis with eosinophilia (Shulman's disease). ( Coombes, BH; Francis, PN; Radvan, GH, 1979) |
| "Eosinophilic fasciitis is a rare connective tissue disorder characterized by inflammation of the fascia that leads to painful, indurated skin." | 1.51 | Eosinophilic fasciitis presenting as a unilateral, solitary plaque. ( Alexanian, C; Cheng, M; Kiuru, M; Le, ST; Tartar, DM; Wang, JZ, 2019) |
| "A middle-aged woman with follicular lymphoma being treated with chemotherapy presented with acute onset atraumatic forearm swelling and severe pain." | 1.42 | Forearm compartment syndrome as a result of eosinophilic fasciitis: case report. ( Alolabi, B; El Bahtimi, R; Jenkinson, RJ; Koo, K; Lesieur, M; Smilovici, B, 2015) |
| "Eosinophilic fasciitis (EF) is a rare inflammatory and fibrosing disorder with clinical, biological and histological characteristics." | 1.35 | [Eosinophilic fasciitis and metastatic choroïdal melanoma: a paraneoplastic syndrome?]. ( Dendale, R; Lumbroso-Le Rouic, L; Récanati, G; Veyssier-Belot, C; Zuech, P, 2008) |
| "Eosinophilic fasciitis (EF) is a rare connective tissue disorder characterized by symmetrical sclerodermatous skin changes primarily affecting the extremities and histologically, by thickening of the fascia with chronic inflammatory infiltrate containing eosinophils." | 1.34 | Eosinophilic fasciitis in a 57-year-old Japanese-American woman. ( Ambrocio, DU; Uramoto, K, 2007) |
| "Eosinophilic fasciitis (EF) and peripheral eosinophilia are rare in children." | 1.32 | Cytokine abnormalities in a patient with eosinophilic fasciitis. ( Dziadzio, L; Huttenlocher, A; Jarjour, N; Kelly, EA; Panzer, SE, 2003) |
| " Corticosteroid treatment (prednisone at the starting dosage of 30 mg/day) produced the healing of the disease in 5 months." | 1.29 | [Scleroderma induced by chemical agents. Description of a case and review of the literature]. ( Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A; Pacor, ML; Spinaci, E, 1995) |
| "The fasciitis and morphea are clearly linked manifestations." | 1.28 | The fasciitis-morphea complex in children. ( Miller, JJ, 1992) |
| "We report a patient with eosinophilic fasciitis, reactive hepatitis and splenomegaly." | 1.28 | Eosinophilic fasciitis presenting with a reactive hepatitis. ( Bijlsma, JW; Derksen, RH; Loeliger, AE; van den Brink, HR, 1991) |
| "Eosinophilic fasciitis is a rare disease characterized by pain, swelling, and tenderness over the extremities, followed by induration of the skin." | 1.28 | Eosinophilic fasciitis during pregnancy. ( Amdur, HS; Levin, RE, 1989) |
| "An 80-year-old woman with eosinophilic fasciitis (EF) is presented." | 1.27 | Eosinophilic fasciitis. Report of a case with features of other autoimmune disease. ( Boiesen, M; Keiding, LM; Thomsen, K, 1983) |
| "The long-term outcome of eosinophilic fasciitis (EF) described for the first time by Shulman in 1974 remains unclear." | 1.27 | [Long-term development of eosinophilic fasciitis. Study of 11 cases]. ( Blétry, O; Etienne, SD; Frances, C; Godeau, P; Herson, S; Le Thi Huong, Du; Mouthon, JM; Piette, JC; Wechsler, B, 1984) |
| "Eosinophilic fasciitis is a syndrome of imprecise classification which usually responds well to corticosteroids." | 1.27 | [Eosinophilic fasciitis. Response to treatment with cimetidine]. ( Betlloch Mas, I; Castells Rodellas, A; Jiménez Martínez, A; Jorda Cuevas, E; Ramón Quiles, D, 1987) |
| "Six patients with diffuse fasciitis are described." | 1.27 | Diffuse (eosinophilic) fasciitis. A series of six cases. ( Cats, A; De Jonge-Bok, JM; Eulderink, F; Steven, MM, 1984) |
| "The term eosinophilic fasciitis is chosen because of the distinct histologic changes occurring in the deep fascia and prominence of eosinophils in the inflammatory reaction." | 1.26 | [Eosinophilic fasciitis]. ( Hohmeister, R, 1982) |
| "Diffuse fasciitis with eosinophilia is a newly recognized connective tissue disease appearing initially to be either scleroderma or dermatomyositis." | 1.26 | Diffuse fasciitis with eosinophilia in childhood. ( Sills, EM, 1982) |
| "Eosinophilic fasciitis is characterized by peripheral eosinophilia, diffuse induration of the skin (particularly of the extremities), thickened fascia, and responsiveness to corticosteroids." | 1.26 | Eosinophilic fasciitis: an underdiagnosed syndrome. ( Friedler, EM; Hines, DA, 1981) |
| "Synovitis has been infrequently reported in eosinophilic fasciitis." | 1.26 | Eosinophilic fasciitis (Shulman syndrome) with prominent synovitis. ( Aelion, JA; Avidor, I; Blum, I; Wysenbeek, AJ, 1982) |
| "The skin lesions varied from morphea, lichen sclerosus, fasciitis, and discoid lupus erythematosus to lupus panniculitis." | 1.26 | Carpal tunnel syndrome in cutaneous connective tissue disease: generalized morphea, lichen sclerosus, fasciitis, discoid lupus erythematosus, and lupus panniculitis. ( Connolly, SM; Doyle, JA; Winkelmann, RK, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (42.86) | 18.7374 |
| 1990's | 9 (12.86) | 18.2507 |
| 2000's | 15 (21.43) | 29.6817 |
| 2010's | 15 (21.43) | 24.3611 |
| 2020's | 1 (1.43) | 2.80 |
| Authors | Studies |
|---|---|
| Alexanian, C | 1 |
| Cheng, M | 1 |
| Kiuru, M | 1 |
| Wang, JZ | 1 |
| Le, ST | 1 |
| Tartar, DM | 1 |
| Erez, D | 1 |
| Shoenfeld, Y | 1 |
| Natour, A | 1 |
| Dovrish, Z | 1 |
| Tayer-Shifman, OE | 1 |
| Levy, Y | 1 |
| Zuelgaray, E | 1 |
| Sallé de Chou, C | 1 |
| Vignon-Pennamen, MD | 1 |
| Battistella, M | 1 |
| Leonard-Louis, S | 1 |
| Hefez, L | 1 |
| Guibal, F | 1 |
| Bagot, M | 1 |
| Bouaziz, JD | 1 |
| Fonseca, MES | 1 |
| Quaresma, MV | 1 |
| Luppino-Assad, AP | 1 |
| da Silva, HC | 1 |
| Andrade, DCO | 1 |
| Sampaio-Barros, PD | 1 |
| Chatterjee, S | 1 |
| Prayson, RA | 1 |
| Verenes, M | 1 |
| Stone, SL | 1 |
| Hobson-Webb, LD | 1 |
| Mhoon, JT | 1 |
| Guidon, AC | 1 |
| De Jesus-Acosta, C | 1 |
| Cartwright, MS | 1 |
| Frikha, F | 1 |
| Bahloul, Z | 1 |
| Pinal-Fernandez, I | 1 |
| Callejas-Moraga, EL | 1 |
| Roade-Tato, ML | 1 |
| Simeon-Aznar, CP | 1 |
| Alolabi, B | 1 |
| Lesieur, M | 1 |
| Smilovici, B | 1 |
| Koo, K | 1 |
| El Bahtimi, R | 1 |
| Jenkinson, RJ | 1 |
| Baird, K | 1 |
| Comis, LE | 1 |
| Joe, GO | 1 |
| Steinberg, SM | 1 |
| Hakim, FT | 1 |
| Rose, JJ | 1 |
| Mitchell, SA | 1 |
| Pavletic, SZ | 1 |
| Figg, WD | 1 |
| Yao, L | 1 |
| Flanders, KC | 1 |
| Takebe, N | 1 |
| Sarantopoulos, S | 1 |
| Booher, S | 1 |
| Cowen, EW | 1 |
| Bachmeyer, C | 1 |
| Moguelet, P | 1 |
| Rein, C | 1 |
| Girot, R | 1 |
| Mendoza, FA | 1 |
| Bai, R | 1 |
| Kebede, AG | 1 |
| Jimenez, SA | 1 |
| Veyssier-Belot, C | 1 |
| Zuech, P | 1 |
| Lumbroso-Le Rouic, L | 1 |
| Récanati, G | 1 |
| Dendale, R | 1 |
| Godeiro-Junior, C | 1 |
| Felicio, AC | 1 |
| Goldzveig, J | 1 |
| Chieia, MA | 1 |
| Schmidt, B | 1 |
| Oliveira, AS | 1 |
| Daniel, RS | 1 |
| Brown, AN | 1 |
| Taylor, WC | 1 |
| Fulton, BN | 1 |
| Persellin, ST | 1 |
| Khanna, D | 1 |
| Agrawal, H | 1 |
| Clements, PJ | 1 |
| Mrabet, D | 1 |
| Saadi, F | 1 |
| Chelly, I | 1 |
| Trojet, S | 1 |
| Zaraa, I | 1 |
| Sahli, H | 1 |
| Haouet, S | 1 |
| Ben Osmane, A | 1 |
| Meddeb, N | 1 |
| Sellami, S | 1 |
| Krishna, K | 1 |
| Yacoub, A | 1 |
| Hutchins, LF | 1 |
| Kortebein, PM | 1 |
| Tsoi, KL | 1 |
| Custers, M | 1 |
| Bij de Vaate, L | 1 |
| Jacobs, JW | 1 |
| Smith, RL | 1 |
| Leaf, FA | 1 |
| Dziadzio, L | 1 |
| Kelly, EA | 1 |
| Panzer, SE | 1 |
| Jarjour, N | 1 |
| Huttenlocher, A | 1 |
| Nakamura, T | 1 |
| Tomoda, K | 1 |
| Yamamura, Y | 1 |
| Tsukano, M | 1 |
| Honda, I | 1 |
| Iyama, K | 1 |
| Ollivier, Y | 1 |
| Andrès, C | 1 |
| Laplaud, AL | 1 |
| Sevin, E | 1 |
| Letellier, P | 1 |
| Briani, C | 1 |
| Scarlato, M | 1 |
| Pavan, A | 1 |
| Marcolongo, R | 1 |
| Rondinone, R | 1 |
| Adami, F | 1 |
| Puszczewicz, M | 1 |
| Zimmermann-Górska, I | 1 |
| Pietrzak-Kaczmarek, H | 1 |
| Lazowski, S | 1 |
| Ambrocio, DU | 1 |
| Uramoto, K | 1 |
| Weber, HO | 1 |
| Schaller, M | 1 |
| Metzler, G | 1 |
| Röcken, M | 1 |
| Berneburg, M | 1 |
| De Jonge-Bok, JM | 1 |
| Steven, MM | 1 |
| Eulderink, F | 2 |
| Cats, A | 1 |
| Herson, S | 1 |
| Piette, JC | 1 |
| Frances, C | 1 |
| Etienne, SD | 1 |
| Le Thi Huong, Du | 1 |
| Mouthon, JM | 1 |
| Blétry, O | 1 |
| Wechsler, B | 1 |
| Godeau, P | 1 |
| Boiesen, M | 1 |
| Keiding, LM | 1 |
| Thomsen, K | 1 |
| Patrone, NA | 1 |
| Kredich, DW | 1 |
| Bertken, R | 1 |
| Shaller, D | 1 |
| Sanchez Roman, J | 1 |
| Pamies Andreu, E | 1 |
| Perez Vega, E | 1 |
| Villar Ortiz, J | 1 |
| Roca Martinez, F | 1 |
| Golitz, LE | 1 |
| Mensing, H | 1 |
| Meigel, W | 1 |
| Jänner, M | 1 |
| Aelion, JA | 1 |
| Wysenbeek, AJ | 1 |
| Avidor, I | 1 |
| Blum, I | 1 |
| Winkelmann, RK | 2 |
| Connolly, SM | 2 |
| Doyle, JA | 2 |
| Solomon, G | 1 |
| Barland, P | 1 |
| Rifkin, H | 1 |
| Caspi, D | 1 |
| Fishel, R | 1 |
| Varon, M | 1 |
| Yona, E | 1 |
| Baratz, M | 1 |
| Yaron, M | 1 |
| Hohmeister, R | 1 |
| Sills, EM | 1 |
| Hines, DA | 1 |
| Friedler, EM | 1 |
| Ambanelli, U | 1 |
| Manganelli, P | 1 |
| Fietta, P | 1 |
| Ferraccioli, GF | 1 |
| Marbini, A | 1 |
| Sansoni, P | 1 |
| Alinovi, A | 1 |
| Michet, CJ | 1 |
| Ginsburg, WW | 1 |
| Biasi, D | 1 |
| Carletto, A | 1 |
| Caramaschi, P | 1 |
| Pacor, ML | 1 |
| Spinaci, E | 1 |
| Bambara, LM | 1 |
| Farrington, ML | 1 |
| Haas, JE | 1 |
| Nazar-Stewart, V | 1 |
| Mellins, ED | 1 |
| Valencia, IC | 1 |
| Chang, A | 1 |
| Kirsner, RS | 1 |
| Kerdel, FA | 2 |
| Bani-Sadr, F | 1 |
| Leautez, S | 1 |
| el Kouri, D | 1 |
| Hamidou, M | 1 |
| Barrier, JH | 1 |
| Raffi, F | 1 |
| Choquet-Kastylevsky, G | 1 |
| Kanitakis, J | 1 |
| Dumas, V | 1 |
| Descotes, J | 1 |
| Faure, M | 1 |
| Claudy, A | 1 |
| Richardson, MW | 1 |
| Funkhouser, WK | 1 |
| Senior, B | 1 |
| Weston, BW | 1 |
| Radvan, GH | 1 |
| Coombes, BH | 1 |
| Francis, PN | 1 |
| Grigoris, I | 1 |
| de Launey, W | 1 |
| Jevtic, AP | 1 |
| Miller, JJ | 2 |
| Loeliger, AE | 1 |
| van den Brink, HR | 1 |
| Derksen, RH | 1 |
| Bijlsma, JW | 1 |
| Quimby, SR | 1 |
| Griffing, WL | 1 |
| Lattmann, J | 1 |
| Adam, H | 1 |
| von Hochstetter, A | 1 |
| Steurer, J | 1 |
| Siegenthaler-Zuber, G | 1 |
| Kaklamanis, P | 1 |
| Vayopoulos, G | 1 |
| Aroni, K | 1 |
| Meletis, J | 1 |
| Jiménez Martínez, A | 1 |
| Jorda Cuevas, E | 1 |
| Ramón Quiles, D | 1 |
| Betlloch Mas, I | 1 |
| Castells Rodellas, A | 1 |
| Markusse, HM | 1 |
| Breedveld, FC | 1 |
| Grisanti, MW | 1 |
| Moore, TL | 1 |
| Osborn, TG | 1 |
| Haber, PL | 1 |
| Blaser, KU | 1 |
| Steiger, U | 1 |
| Würsch, A | 1 |
| Speck, B | 1 |
| Amdur, HS | 1 |
| Levin, RE | 1 |
| Falanga, V | 1 |
| Soter, NA | 1 |
| Eggelmeijer, F | 1 |
| MacFarlane, JD | 1 |
| Dijkmans, BA | 1 |
| Pollack, MS | 1 |
| Short, HD | 1 |
| Young, JB | 1 |
| Piwinski, SE | 1 |
| Callaway, C | 1 |
| Debakey, ME | 1 |
| Williams, HJ | 1 |
| Ziter, FA | 1 |
| Banta, CA | 1 |
| Beaucher, WN | 1 |
| Skov, BG | 1 |
| Silverman, ED | 1 |
| Adornato, BT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease[NCT00702689] | Phase 2 | 20 participants (Actual) | Interventional | 2008-12-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
One or more joints were assessed for ROM deficit by a physiatrist with expertise in graft versus host disease and joint ROM. (NCT00702689)
Timeframe: 6 months
| Intervention | Percent change (Mean) |
|---|---|
| Imatinib Mesylate in Patients With cGVHD | 24.2 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00702689)
Timeframe: Date treatment consent signed to date off study, approximately, 41 months, 27 days
| Intervention | Participants (Number) |
|---|---|
| Imatinib Mesylate in Patients With cGVHD | 20 |
Change in immunosuppression was defined by an increase or decrease in steroid use form baseline. (NCT00702689)
Timeframe: 6 months
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ↓ Pred 20 mg everyday (qd )to 5 mg every other day | ↓ MPred 16 mg every other day(qod) to 4 mg qod | ↓ Pred:24mg every day(qd) to 20mg qd | No change | ↓ Tacro 2mg every am 1.5mg every pm to .5mg bid | Pred↓ 25mg qd to 15mg qd;Tacro↓ 2mg bid to 1mg bid | Pred↓ 2.5mg qd to 2.5mg every other day | ↓ Siro:2mg qd to 1 mg qd | Pred wean then ↑ 10 12.5mg bid;Tacro↑1.0 to 1.5bid | MMF↓ 1g/bid to discontinued | |
| Imatinib Mesylate in Patients With cGVHD | 1 | 1 | 1 | 5 | 1 | 1 | 1 | 1 | 1 | 1 |
Lung function was graded by the National Institutes of Health Chronic Graft Versus Host Disease organ response criteria. The Lung function score = forced expiratory volume 1 (FEV1) score + carbon monoxide diffusing capacity (DLCO) score, with a possible range of 2 (better outcome)-12 (worst outcome). The percent predicted FEV1 and DLCO (adjusted for hematocrit but not alveolar volume) should be converted to a numeric score as follows: >80% =1; 70-79% = 2; 60-69% = 3; 50-59% = 4; 40-49% = 5; <40% = 6. (NCT00702689)
Timeframe: Baseline and 6 Months
| Intervention | units on a scale (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient #2 at Baseline | Patient #2 at 6 Months | Patient #3 at Baseline | Patient #3 at 6 Months | Patient #7 at Baseline | Patient #7 at 6 Months | Patient #8 at Baseline | Patient #8 at 6 Months | Patient #10 at Baseline | Patient #10 at 6 Months | Patient #12 at Baseline | Patient #12 at 6 Months | Patient #13 at Baseline | Patient #13 at 6 Months | Patient #14 at Baseline | Patient #14 at 6 Months | Patient # 15 at Baseline | Patient #15 at 6 Months | Patient #16 at Baseline | Patient #16 at 6 Months | Patient #17 at Baseline | Patient #17 at 6 months | Patient #18 at Baseline | Patient #18 at 6 Months | Patient #19 at Baseline | Patient #19 at 6 Months | Patient #20 at Baseline | Patient #20 at 6 Months | |
| Imatinib Mesylate in Patients With cGVHD | 2 | 2 | 9 | NA | 3 | 8 | 5 | 6 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 5 | 7 | 6 | 3 | 2 | 5 | 6 | 8 | 8 | 9 | 9 | 2 | 2 |
A change in ROM is 25% or greater from baseline. A partial response required improvement in 25% or more in ROM. Progression required 25% or greater loss of ROM.Patients with negative values in the Table are those who lost ROM. Percent improvement in ROM for 1-3 target joints. For patients with >1 target joint, the average ROM improvement was calculated. The average percentage change in ROM deficit from baseline to 6 months was obtained based on the number of degrees of ROM change (6 months)/total ROM deficit (baseline) at each joint. (NCT00702689)
Timeframe: 6 months
| Intervention | Percent change from baseline (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 2 6mo response% change in deficit from baseline | Pt 7 6mo response% change in deficit from baseline | Pt 8 6mo response% change in deficit from baseline | Pt10 6mo response% change in deficit from baseline | Pt12 6mo response% change in deficit from baseline | Pt13 6mo response% change in deficit from baseline | Pt14 6mo response% change in deficit from baseline | Pt15 6mo response% change in deficit from baseline | Pt16 6mo response% change in deficit from baseline | Pt17 6mo response% change in deficit from baseline | Pt18 6mo response% change in deficit from baseline | Pt19 6mo response% change in deficit from baseline | Pt20 6mo response% change in deficit from baseline | |
| Imatinib Mesylate in Patients With cGVHD | 94 | 35 | 16 | 21 | 16 | 61 | 27 | 22 | 3 | -25 | -2 | 31 | 15 |
Progressive disease is defined as joint ROM: decrease of >25% in composite ROM score on 2 consecutive evaluations at least 2 weeks apart, but not greater than 4 weeks apart or steroid pulse: >1 steroid pulse per 3 month period if administered for sclerotic-type chronic graft versus host disease (ScGVHD). Response is joint ROM: increase of >25% in composite ROM score. Maximal response is a response with no further improvement over 2 sequential 3-month evaluations. Stable disease does not meet the criteria for progression, response, or maximal response. (NCT00702689)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| Partial Response | Stable Disease | Progressive Disease | |
| Imatinib Mesylate in Patients With cGVHD | 5 | 7 | 2 |
The provider global rating is a physician impression of severity of cGVHD symptoms from a scale of zero (no symptoms) to 10 (most severe GVHD symptoms possible). (NCT00702689)
Timeframe: Baseline and 6 months
| Intervention | Provider Global Rating Score (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient #2 at Baseline | Patient #2 at 6 Months | Patient #3 at Baseline | Patient #3 at 6 Months | Patient #7 at Baseline | Patient #7 at 6 Months | Patient #8 at Baseline | Patient #8 at 6 Months | Patient #10 at Baseline | Patient #10 at 6 Months | Patient #12 at Baseline | Patient #12 at 6 Months | Patient #13 at Baseline | Patient #13 at 6 Months | Patient #14 at Baseline | Patient #14 at 6 Months | Patient # 15 at Baseline | Patient #15 at 6 Months | Patient #16 at Baseline | Patient #16 at 6 Months | Patient #17 at Baseline | Patient #17 at 6 months | Patient #18 at Baseline | Patient #18 at 6 Months | Patient #19 at Baseline | Patient #19 at 6 Months | Patient #20 at Baseline | Patient #20 at 6 Months | |
| Imatinib Mesylate in Patients With cGVHD | 5 | 4 | 3 | NA | 6 | 8 | 6 | 7 | 5 | 4 | 6 | 7 | 6 | 4 | 7 | 6 | 7 | 6 | 5 | 4 | 6 | 8 | 8 | 8 | 8 | 5 | 8 | 8 |
Total skin score was graded by the National Institutes of Health Consensus Criteria. Skin score was calculated by dividing the total score by seven domains (skin, eye, oral, joint, gastrointestinal, hepatic, pulmonary) in men and 8 domains in women (previous domains noted plus gynecologic). Total skin score is a percentage of body surface area (BSA) involvement (range 0-100%). It was calculated from the sum of moveable body surface BSA and non-moveable BSA. Higher numbers = greater body surface area affected. (NCT00702689)
Timeframe: Baseline and 6 Months
| Intervention | units on a scale (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient # 2 - Baseline | Patient # 2 - 6 months | Patient # 3 - Baseline | Patient # 3 - 6 months | Patient # 7 - Baseline | Patient # 7 - 6 months | Patient # 8 - Baseline | Patient # 8 - 6 months | Patient # 10 - Baseline | Patient # 10 - 6 months | Patient # 12 - Baseline | Patient # 12 - 6 months | Patient # 13 - Baseline | Patient # 13 - 6 months | Patient # 14 - Baseline | Patient # 14 - 6 months | Patient # 15 - Baseline | Patient # 15 - 6 months | Patient # 16 - Baseline | Patient # 16 - 6 months | Patient # 17 - Baseline | Patient # 17 - 6 months | Patient # 18 - Baseline | Patient # 18 - 6 months | Patient # 19 - Baseline | Patient # 19 - 6 months | Patient # 20 - Baseline | Patient # 20 - 6 months | |
| Imatinib Mesylate in Patients With cGVHD | 66.6 | 54 | 43.38 | NA | 66.24 | 55.53 | 53.1 | 55.26 | 10.8 | 6.12 | 21.24 | 30.06 | 79.2 | 62.28 | 39.96 | 40.5 | 71.46 | 61.83 | 9.54 | 8.1 | 84.96 | 85.11 | 26.64 | 24.3 | 21.15 | 37.8 | 23.4 | 25.2 |
9 reviews available for prednisone and Fasciitis
| Article | Year |
|---|---|
Clinical experience with biologic treatment in resistant eosinophilic fasciitis: Case reports and review of the literature.
Topics: Azathioprine; Biological Products; Biopsy; Dose-Response Relationship, Drug; Drug Resistance; Drug T | 2021 |
[Sarcoid-like granulomatosis associated with eosinophilic fasciitis].
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Diagnosis, Differential; Eosinophilia; Fasciitis; Granu | 2018 |
Eosinophilic fasciitis during pregnancy: case report and review of literature.
Topics: Biopsy; Eosinophilia; Fasciitis; Female; Glucocorticoids; Humans; Live Birth; Prednisone; Pregnancy; | 2018 |
Palmar fasciitis with polyarthritis syndrome in a patient with breast cancer.
Topics: Adult; Anti-Inflammatory Agents; Arthritis; Breast Neoplasms; Carcinoma, Ductal; Combined Modality T | 2011 |
Polyarteritis nodosa limited to calf muscles: a case report and review of the literature.
Topics: Adult; Anti-Inflammatory Agents; Biopsy; Carrier State; Fasciitis; Female; Hepatitis B; Humans; Magn | 2003 |
Fasciitis with eosinophilia: The Shulman syndrome.
Topics: Eosinophilia; Fasciitis; Humans; Physical Exertion; Prednisone; Syndrome | 1980 |
Diffuse fasciitis with eosinophilia (Shulman's disease).
Topics: Eosinophilia; Fasciitis; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone | 1979 |
Eosinophilic fasciitis in children.
Topics: Child, Preschool; Contracture; Eosinophilia; Fasciitis; Humans; Joint Diseases; Male; Prednisone; Sk | 1989 |
[Eosinophilic fasciitis with aplastic anemia and Hashimoto's thyroiditis. Review of the literature and report of a typical example].
Topics: Anemia, Aplastic; Electromyography; Eosinophilia; Fasciitis; Female; Humans; Middle Aged; Prednisone | 1989 |
2 trials available for prednisone and Fasciitis
| Article | Year |
|---|---|
Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Drug Administration Schedule; Fasciitis; Female; Gr | 2015 |
Severe eosinophilic fasciitis: comparison of treatment with D-penicillamine plus corticosteroids vs. corticosteroids alone.
Topics: Adult; Aged; Antirheumatic Agents; Drug Therapy, Combination; Eosinophilia; Fasciitis; Female; Gluco | 2016 |
59 other studies available for prednisone and Fasciitis
| Article | Year |
|---|---|
Eosinophilic fasciitis presenting as a unilateral, solitary plaque.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Clobetasol; Eosinophilia; Fasciitis; Fe | 2019 |
Diffuse skin thickening, myalgias and joint stiffness in a 41-year-old man.
Topics: Adult; Anti-Inflammatory Agents; Diagnosis, Differential; Eosinophilia; Fasciitis; Humans; Joints; M | 2018 |
Neuromuscular ultrasound findings in eosinophilic fasciitis: A case series and literature review.
Topics: Adolescent; Anti-Inflammatory Agents; Eosinophilia; Eosinophils; Fasciitis; Humans; Leukocyte Count; | 2018 |
[Fasciitis with hypereosinophilia (Shulman syndrome) in a 34 year old woman].
Topics: Adult; Anti-Inflammatory Agents; Eosinophilia; Fasciitis; Female; Humans; Prednisone; Synovitis | 2013 |
Groove sign in eosinophilic fasciitis.
Topics: Aged; Arthralgia; Drug Therapy, Combination; Edema; Eosinophilia; Fasciitis; Female; Follow-Up Studi | 2014 |
Forearm compartment syndrome as a result of eosinophilic fasciitis: case report.
Topics: Anti-Inflammatory Agents; Comorbidity; Compartment Syndromes; Decompression, Surgical; Eosinophilia; | 2015 |
Facial lesions heralding the onset and relapse of eosinophilic fasciitis.
Topics: Adult; Arthritis; Biopsy; Chronic Disease; Colchicine; Edema; Eosinophilia; Fascia; Fasciitis; Folic | 2016 |
[Eosinophilic fasciitis and metastatic choroïdal melanoma: a paraneoplastic syndrome?].
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Anti-Inflammatory Agents; An | 2008 |
An amyotrophic lateral sclerosis mimicker: eosinophilic fasciitis.
Topics: Adult; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents; Biopsy; Diagnosis, Differential; Ele | 2008 |
Case report of unilateral eosinophilic fasciitis in a Vietnamese woman.
Topics: Adult; Biopsy; Eosinophilia; Fasciitis; Female; Humans; Prednisone; Skin; Vietnam | 2009 |
Eosinophilic fasciitis in a duathlete.
Topics: Eosinophilia; Fasciitis; Female; Glucocorticoids; Humans; Magnetic Resonance Imaging; Middle Aged; P | 2009 |
Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Drug Therapy, Combination; Eosinophilia; Fasciitis | 2010 |
A case of Shulman disease in a patient with systemic lupus erythematosus.
Topics: Eosinophilia; Fasciitis; Female; Glucocorticoids; Humans; Lupus Erythematosus, Systemic; Prednisone; | 2010 |
Eosinophilic fasciitis.
Topics: Anti-Inflammatory Agents; Eosinophilia; Fasciitis; Female; Forearm; Humans; Middle Aged; Prednisone; | 2012 |
Indurated plaques on the arms.
Topics: Biopsy, Needle; Eosinophilia; Fasciitis; Follow-Up Studies; Humans; Immunohistochemistry; Male; Midd | 2002 |
Cytokine abnormalities in a patient with eosinophilic fasciitis.
Topics: Anti-Inflammatory Agents; Arm; Child, Preschool; Cytokines; Eosinophilia; Eosinophils; Fasciitis; Fe | 2003 |
[Palmar fasciitis after carboplatin administration for an ovarian adenocarcinoma].
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Carboplatin; Cystadenocarcinoma, Papillary; F | 2006 |
Polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes: not always a POEMS syndrome.
Topics: Cyclosporine; Diagnostic Errors; Eosinophilia; Fasciitis; Hepatomegaly; Humans; Hyperpigmentation; I | 2006 |
[Diagnostic problems in eosinophilic fasciitis].
Topics: Adult; Biopsy; Chronic Disease; Diagnosis, Differential; Eosinophilia; Eosinophilia-Myalgia Syndrome | 2006 |
Eosinophilic fasciitis in a 57-year-old Japanese-American woman.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diagnosis, Differential; Eosinophilia; Fasciitis | 2007 |
Eosinophilic fasciitis and combined UVA1--retinoid--corticosteroid treatment: two case reports.
Topics: Adult; Aged; Dermatologic Agents; Eosinophilia; Fasciitis; Glucocorticoids; Humans; Isotretinoin; Ma | 2008 |
Diffuse (eosinophilic) fasciitis. A series of six cases.
Topics: Adolescent; Adult; Child; Eosinophilia; Fascia; Fasciitis; Female; Humans; Male; Middle Aged; Predni | 1984 |
[Long-term development of eosinophilic fasciitis. Study of 11 cases].
Topics: Adult; Aged; Cimetidine; Colchicine; Eosinophilia; Factor XIII; Fasciitis; Female; Humans; Male; Mid | 1984 |
Eosinophilic fasciitis. Report of a case with features of other autoimmune disease.
Topics: Aged; Autoimmune Diseases; Eosinophilia; Fasciitis; Female; Humans; Immunoglobulin M; Prednisone | 1983 |
Eosinophilic fasciitis in a child.
Topics: Arthritis, Juvenile; Child; Diagnosis, Differential; Eosinophilia; Fasciitis; Humans; Male; Metacarp | 1984 |
Chronic progressive eosinophilic fasciitis: report of a 20-year failure to attain remission.
Topics: Adult; Chronic Disease; Eosinophilia; Fasciitis; Humans; Male; Prednisone; Time Factors | 1983 |
[Eosinophilic fasciitis. Analysis of 3 new cases with atypical characteristics].
Topics: Adult; Biopsy; Eosinophilia; Fascia; Fasciitis; Female; Humans; Male; Middle Aged; Prednisone | 1983 |
[Diffuse fasciitis with eosinophilia (Shulman-syndrome) (author's transl)].
Topics: Cyclophosphamide; Drug Therapy, Combination; Eosinophilia; Fasciitis; Humans; Lipoma; Male; Methylpr | 1982 |
Eosinophilic fasciitis (Shulman syndrome) with prominent synovitis.
Topics: Eosinophilia; Fascia; Fasciitis; Humans; Male; Middle Aged; Prednisone; Synovitis | 1982 |
Carpal tunnel syndrome in cutaneous connective tissue disease: generalized morphea, lichen sclerosus, fasciitis, discoid lupus erythematosus, and lupus panniculitis.
Topics: Adult; Carpal Tunnel Syndrome; Fasciitis; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, D | 1982 |
Eosinophilic fasciitis responsive to cimetidine.
Topics: Cimetidine; Eosinophilia; Fasciitis; Guanidines; Humans; Male; Middle Aged; Prednisone; Receptors, H | 1982 |
Multisystem presentation of eosinophilic fasciitis.
Topics: Adult; Ankle Joint; Azathioprine; Blood Sedimentation; Bone Marrow Examination; Elbow Joint; Eosinop | 1982 |
[Eosinophilic fasciitis].
Topics: Adult; Eosinophilia; Fasciitis; Female; Humans; Male; Middle Aged; Prednisone | 1982 |
Diffuse fasciitis with eosinophilia in childhood.
Topics: Adolescent; Dermatomyositis; Diagnosis, Differential; Eosinophilia; Fasciitis; Female; Humans; Immun | 1982 |
Eosinophilic fasciitis: an underdiagnosed syndrome.
Topics: Adult; Eosinophilia; Fasciitis; Humans; Male; Middle Aged; Prednisone | 1981 |
[Eosinophilic fasciitis. Description of a clinical case with Raynaud's phenomenon].
Topics: Adult; Eosinophilia; Fasciitis; Humans; Male; Prednisone; Raynaud Disease | 1981 |
Eosinophilic fasciitis: report of 15 cases.
Topics: Adult; Aged; Child; Eosinophilia; Fascia; Fasciitis; Female; Humans; Male; Middle Aged; Prednisone; | 1981 |
[Scleroderma induced by chemical agents. Description of a case and review of the literature].
Topics: Adult; Eosinophilia; Fasciitis; Free Radicals; Humans; Male; Prednisone; Scleroderma, Systemic; Sodi | 1995 |
Eosinophilic fasciitis in children frequently progresses to scleroderma-like cutaneous fibrosis.
Topics: Adolescent; Biopsy; Child; Child, Preschool; Eosinophilia; Fasciitis; Female; Fibrosis; Humans; Male | 1993 |
Eosinophilic fasciitis responsive to treatment with pulsed steroids and cyclosporine.
Topics: Anti-Inflammatory Agents; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Eosinophilia | 1999 |
[Value of immunoglobulins in Schulman fasciitis].
Topics: Adolescent; Biopsy; Combined Modality Therapy; Eosinophilia; Fascia; Fasciitis; Humans; Immunization | 2000 |
Eosinophilic fasciitis and simvastatin.
Topics: Aged; Anti-Inflammatory Agents; Eosinophilia; Fasciitis; Female; Humans; Prednisone; Simvastatin | 2001 |
Spindle cell lesions of the head and neck mimicking rhabdomyosarcoma in children.
Topics: Child; Diagnosis, Differential; Fasciitis; Female; Head and Neck Neoplasms; Humans; Neoplasms, Muscl | 2002 |
Eosinophilic fasciitis associated with L-tryptophan ingestion.
Topics: Adult; Eosinophilia; Fasciitis; Humans; Male; Prednisone; Tryptophan | 1992 |
The fasciitis-morphea complex in children.
Topics: Adolescent; Antibodies, Antinuclear; Biopsy; Blood Sedimentation; Child; Child, Preschool; Eosinophi | 1992 |
Eosinophilic fasciitis presenting with a reactive hepatitis.
Topics: Adult; Eosinophilia; Fasciitis; Hepatitis; Hepatomegaly; Humans; Liver; Male; Prednisone; Splenomega | 1991 |
Scleroderma and L-tryptophan: a possible explanation of the eosinophilia-myalgia syndrome.
Topics: Adult; Aged; Eosinophilia; Fasciitis; Female; Humans; Kynurenine; Middle Aged; Myositis; Prednisone; | 1990 |
[Eosinophilic fasciitis (Shulman's syndrome)].
Topics: Adult; Arm; Biopsy; Chronic Disease; Eosinophilia; Fasciitis; Humans; Leg; Male; Prednisone; Syndrom | 1990 |
Eosinophilic fasciitis with thrombocytopenia and Dupuytren's contracture.
Topics: Dupuytren Contracture; Eosinophilia; Fasciitis; Female; Humans; Middle Aged; Prednisone; Thrombocyto | 1990 |
[Eosinophilic fasciitis. Response to treatment with cimetidine].
Topics: Cimetidine; Eosinophilia; Fasciitis; Histamine Release; Humans; Male; Middle Aged; Prednisone | 1987 |
Rheumatoid arthritis with eosinophilic fasciitis and pure red cell aplasia.
Topics: Arthritis, Rheumatoid; Eosinophilia; Fasciitis; Female; Humans; Middle Aged; Prednisone; Red-Cell Ap | 1989 |
Eosinophilic fasciitis during pregnancy.
Topics: Biopsy; Cryosurgery; Diagnosis, Differential; Eosinophilia; Fascia; Fasciitis; Female; Humans; Middl | 1989 |
Increased plasma histamine level in eosinophilic fasciitis.
Topics: Adult; Aged; Biopsy; Eosinophilia; Fasciitis; Female; Histamine; Humans; Mast Cells; Middle Aged; Pr | 1989 |
[A fascinating disease?].
Topics: Adult; Eosinophilia; Fascia; Fasciitis; Female; Humans; Male; Middle Aged; Prednisone | 1989 |
Graft stability in a heart transplant recipient whose immunosuppressive therapy was discontinued for 8 months.
Topics: Cholecystitis; Cyclosporins; Disease Susceptibility; Fasciitis; Graft Survival; Heart Transplantatio | 1988 |
Childhood eosinophilic fasciitis--progression to linear scleroderma.
Topics: Child, Preschool; Eosinophilia; Fasciitis; Female; Humans; Prednisone; Scleroderma, Localized | 1986 |
Fasciitis with eosinophilia: a case report.
Topics: Adult; Eosinophilia; Fasciitis; Humans; Hypergammaglobulinemia; Immunoglobulin G; Male; Prednisone | 1985 |
[Eosinophilic fasciitis. A review and a characteristic case report].
Topics: Eosinophilia; Fasciitis; Humans; Male; Middle Aged; Prednisone; Skin | 1985 |
Eosinophilic fasciitis in a two-year-old child.
Topics: Biopsy; Child, Preschool; Eosinophilia; Fasciitis; Female; Humans; Muscles; Prednisone; Scleroderma, | 1985 |